Pfizer's Weight Loss Drug Discontinuation Causes Stock Drop.
Pfizer's stock is down 3% after announcing the discontinuation of its experimental weight loss drug, lotiglipron, while continuing to develop a separate weight loss drug, danuglipron. This news is positive for already established weight loss drugs on the market, such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro.